A rationally designed CD19 monoclonal antibody-triptolide conjugate for the treatment of systemic lupus erythematosus.

Consistently, ADC-TP also reduced Upro levels, and although the difference did not reach statistical significance, it was still superior to TP, TP-PEG, and CD19 mAb treatments ( Fig. 4 D).

also in 111,027 other papers

Upon ADC-TP treatment, the frequencies of splenic naïve B cells and memory B cells were not obviously changed, but the numbers of splenic naïve B cells and memory B cells both show a decreasing trend ( Fig.

also in 47,180 other papers